Solventum Corporation (SOLV)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 7,281 | 8,171 | 8,130 | 8,197 | 8,254 | 8,325 | 8,310 | 8,240 |
| Operating profit | $m | 2,181 | 2,077 | ||||||
| Net profit | $m | 1,138 | 1,460 | 1,343 | 1,346 | 479 | 1,556 | 1,434 | 1,249 |
| EPS reported | $ | 8.88 | 8.19 | ||||||
| Operating cashflow per share | $ | 2.12 | 1.20 | ||||||
| Capex per share | $ | 2.18 | 1.88 | ||||||
| FCF per share | $ | -0.06 | -0.68 | ||||||
| Free cash flow | $m | -10 | -118 | ||||||
| Net debt | $m | 4,157 | 4,883 | ||||||
| Book value equity | $m | 5,049 | 4,800 | ||||||
| Book value per share | $ | 28.80 | 27.52 | ||||||
| Number of shares | m | 175.3 | 174.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 8.92 | 10.93 | ||||||
| P/B LTM | x | 2.73 | 2.87 | ||||||
| P/S LTM | x | 1.66 | 1.66 | ||||||
| P/FCF LTM | x | -1,379.57 | -116.91 | ||||||
| EV/EBITDA LTM | x | 7.04 | 6.91 | ||||||
| EV/Sales LTM | x | 2.16 | 2.43 | ||||||
| Earnings Yield LTM | % | +11.21% | +9.15% | ||||||
| FCF Yield | % | -0.07% | -0.86% | ||||||
| Quality | |||||||||
| ROE | % | +30.82% | +28.96% | ||||||
| ROIC | % | +17.76% | +15.85% | ||||||
| Operating margin | % | +26.20% | +24.99% | ||||||
| Gross margin | % | +53.47% | +54.69% | ||||||
| FCF/Sales | % | -0.12% | -1.42% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +221.74% | +196.74% | ||||||
| Sales Growth YoY | % | +0.86% | +0.68% | ||||||
| Net Income Growth YoY | % | +224.84% | +199.37% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +110.52% | +100.48% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.00 | -0.02 | ||||||
| Net Debt/EBITDA | x | 1.63 | 1.88 | ||||||
| EBIT/Net interest | x | 6.29 | 7.81 | ||||||
| Net debt/market cap | % | +36.50% | +33.11% | ||||||
| Net debt/Equity | x | 0.82 | 1.02 | ||||||
| Gross debt/equity | x | 1.00 | 1.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free